Home > Urology > EAU 2021 > Testis and Penile Cancer > Best of EAU: New advances in testicular and penile cancer

Best of EAU: New advances in testicular and penile cancer

Presented By
Prof. Maarten Albersen, UZ Leuven, Belgium
Conference
EAU 2021
Analysis of microRNA (miRNA) expression allowed to discriminate between viable tumour, teratoma, and necrosis on post-chemotherapy retroperitoneal lymph node dissection (RPLND). A retrospective study underlined that sequential post-chemotherapy residual tumour resection is mandatory. These and other findings were presented in the Best of EAU21 session by Prof. Maarten Albersen (UZ Leuven, Belgium) [1]. Biomarker-guided therapy could reduce overtreatment with post-chemotherapy RPLND in patients with only necrosis in the specimen. Therefore, a German study aimed to identify a combination of miRNAs as potential biomarkers to differentiate between viable tumour, teratoma, and necrosis [2]. miRNA expression was analysed using quantitative real-time PCR (qRT-PCR) in post-chemotherapy RPLND tissues containing necrosis (n=16), teratoma (n=16), and viable tumour (n=16). When comparing viable tumour versus necrosis, miR-371-3p achieved the highest fold chang...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on